Elevate Medical Affairs Podcast Channel Expedited Pharma Publishing: Solutions, Struggles, and Strategic Importance
May 13, 2025
Join Sam Matthew, an independent consultant at Inago Life Sciences specializing in expedited publications, alongside Raghuraj Putage, the function head of medical communications at Inago. They delve into the critical role of expedited publications during health emergencies like COVID-19, emphasizing the balance between speed and research integrity. The duo discusses the transformative impact these publications have on therapies such as gene and CAR T-cell therapies and the ethical challenges faced, advocating for transparency in the fast-paced pharmaceutical landscape.
AI Snips
Chapters
Transcript
Episode notes
Expedited Publishing Process Complexity
- Expedited publications in pharma start internally before study completion, unlike academic publishing which starts post submission.
- This early start increases complexity due to coordination among multiple stakeholders.
Why Expedited Publications Matter
- Expedited publications enable rapid sharing of crucial findings leading to faster breakthroughs and better decision-making.
- They also critically accelerate drug approvals by streamlining regulatory reviews to get treatments to patients sooner.
Expedited Publishing Beyond COVID
- Gene therapy for inherited eye diseases and CAR-T cell therapy for blood cancers demonstrate expedited publishing's role in rapid treatment adoption.
- Early COVID treatments and breakthrough diabetes drugs highlight continual expedited publishing benefits beyond pandemics.